Roivant Sciences on Wednesday checked off another milestone in its attempt to build a franchise drug in autoimmune diseases.
The biotech said two trials for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.